|
VaxGen issues statement on clinical trial data analysis VaxGen release In response to media inquires, VaxGen, Inc. (Nasdaq: VXGN) issued the following statement: VaxGen's analysis of data from its Phase III clinical trial of AIDSVAX B/B followed a statistical analysis plan that was agreed on in advance with the U.S. Food and Drug Administration (FDA). The statistical analysis plan included analyses of various subgroups, including racial backgrounds. The results VaxGen reported on Monday remain accurate as stated, and the analysis continues.
—Posted: February 28, 2003
More news headlines: This week | Last week | Search archive
|
